Loading...
Date of Award
Spring 2021
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Amanda Seymour
Abstract
Urothelial carcinoma (UC) treatment largely relies on surgery and platinum chemotherapies. Unfortunately, platinum chemotherapies have adverse effects (AE) that result in discontinuation and ineligibility of therapy. Novel immunotherapies have been found to have not only a safer treatment profile versus platinum chemotherapy, but are also efficacious in the treatment of in high-grade UC.
Recommended Citation
Smith, Rachel, "The efficacy and safety of novel immunotherapy agent in high-grade urothelial carcinoma" (2021). Capstone Showcase. 51.
https://scholarworks.arcadia.edu/showcase/2021/pa/51
Additional Files
Rachel Smith - Immunotherapy for UCa References.pdf (93 kB)Rachel Smith - Immunotherapy and UC.pdf (198 kB)
Rachel Smith - Immunotherapy and UC Poster.pdf (715 kB)
The efficacy and safety of novel immunotherapy agent in high-grade urothelial carcinoma
Urothelial carcinoma (UC) treatment largely relies on surgery and platinum chemotherapies. Unfortunately, platinum chemotherapies have adverse effects (AE) that result in discontinuation and ineligibility of therapy. Novel immunotherapies have been found to have not only a safer treatment profile versus platinum chemotherapy, but are also efficacious in the treatment of in high-grade UC.